A phase 3 study to evaluate the efficacy and safety of TAK-390MR [dexlansoprazole] (60 mg QD and 90 mg QD) and an active comparator, lansoprazole (30 mg QD) on healing of erosive esophagitis

Trial Profile

A phase 3 study to evaluate the efficacy and safety of TAK-390MR [dexlansoprazole] (60 mg QD and 90 mg QD) and an active comparator, lansoprazole (30 mg QD) on healing of erosive esophagitis

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs Dexlansoprazole (Primary) ; Lansoprazole
  • Indications Erosive oesophagitis
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda; TAP Pharmaceuticals
  • Most Recent Events

    • 30 Sep 2013 Post-hoc pooled analysis published in Alimentary Pharmacology and Therapeutics.
    • 12 May 2009 ClinicalTrials.gov has reported as company added as trial sponsor, affiliate and additional location identified.
    • 11 May 2009 Results have been reported in Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top